The new “vitamin” hiding in your mushrooms

Your Microbiome Treats Mushrooms Differently From Any Vegetable. Here Is the Science.

Fungi are closer to animals than to plants, their cell walls are recognised by your immune system in a way no vegetable triggers, and one fungal compound may be a vitamin we have quietly been missing. A BiomeSci evidence review.

Most people file mushrooms next to broccoli and lettuce, a vegetable by association. Your biology does not make that mistake. Fungi belong to their own kingdom, and the compounds in a mushroom engage your gut, immune system, and brain along pathways that plant foods simply do not share. To understand why, you have to start with an uncomfortable fact about what a mushroom actually is.

Why your body reads fungi as kin, not produce

For most of the twentieth century, fungi were classified as plants. Molecular biology ended that. When researchers first compared the genes of animals, fungi, and plants, animals and fungi turned out to share a more recent common ancestor with each other than either does with plants, a grouping later named the Opisthokonta (Wainright et al., 1993). Decades of comparative genomics have since hardened that finding into consensus (Sebé-Pedrós et al., 2017).

The kinship is biochemical, not cosmetic. Like us, fungi are heterotrophs that cannot photosynthesise and must consume other organisms for energy, while plants build their own food from sunlight (Sebé-Pedrós et al., 2017). This matters for the gut because the human immune system evolved alongside fungi and learned to recognise their signature cell-wall carbohydrates with precision. A mushroom’s cell wall is not generic roughage. It carries molecular patterns your gut-immune interface is specifically built to read.

The fungal fibre your immune system is tuned to detect

That signature carbohydrate is beta-glucan, a complex sugar that makes up much of the fungal cell wall. In humans, a portion of ingested beta-glucan is sensed by receptors on immune cells, including Dectin-1, concentrated at the gut barrier where most of the body’s immune tissue sits. The downstream effect on infection risk is now backed by human trials rather than theory. A meta-analysis of thirteen randomised controlled trials found that beta-glucan supplementation significantly reduced the incidence of upper respiratory tract infections, shortened their duration, and cut the average number of episodes (Zhong et al., 2021). A separate systematic review of thirty-four randomised trials of fungal beta-glucans, including preparations from oyster, shiitake, and reishi mushrooms, found their main consistent benefit was immune modulation that reduced cold, flu, and allergy symptoms, with no glucan-related adverse events (Maheshwari et al., 2021).

Two honest caveats keep this in proportion. Most of those trials used yeast-derived or concentrated glucan, often at doses below what you would get from a meal of mushrooms, so the size of the benefit from eating mushrooms specifically is not pinned down (Maheshwari et al., 2021). And the well-known cholesterol-lowering power of beta-glucan, confirmed across twenty-eight randomised trials, was demonstrated for soluble beta-glucan from oats and barley, not the fungal type, so it should not simply be transferred to mushrooms (Whitehead et al., 2014).

What mushrooms actually do to the microbiome

Here is where BiomeSci parts company with the hype. Mushroom fibre is often sold as a gut “prebiotic” that feeds bacteria and raises short-chain fatty acids. The human evidence is thinner than that claim implies. In the best-controlled trial to date, a randomised crossover study, adults eating roughly 226 grams of white button mushrooms twice daily shifted their microbial composition, with greater abundance of Bacteroidetes and lower Firmicutes, and produced heavier stools, but showed no change in short-chain fatty acid concentrations, and undigested mushroom fragments appeared in nearly a third of stool samples (Hess et al., 2018). So mushrooms do appear to nudge the microbiome, but the popular short-chain-fatty-acid story rests mostly on laboratory fermentation studies, not on people. Treat mushrooms as a promising microbiome input, not a proven prebiotic.

The gut-brain angle, now backed by cohorts that followed people for years

The cognitive findings have graduated from snapshots to long-term follow-up. In the Ohsaki cohort of more than thirteen thousand older Japanese adults tracked for around six years, those eating mushrooms three or more times a week had a 19 percent lower risk of developing dementia than infrequent consumers (Zhang et al., 2017). The Circulatory Risk in Communities Study, following nearly four thousand adults for a median of sixteen years, found a substantially lower risk of disabling dementia among higher mushroom consumers, although the effect reached significance only in women (Aoki et al., 2024). The EPIC-Norfolk cohort, tracking intake over eighteen years, linked regular mushroom eating to better cognitive performance in a dose-dependent way (Cha et al., 2024).

Small randomised trials point the same direction. A sixteen-week double-blind trial of lion’s mane mushroom (Hericium erinaceus) improved cognitive scores in older adults with mild impairment, with the benefit fading once supplementation stopped (Mori et al., 2009). A year-long pilot trial of ergothioneine, the mushroom compound discussed below, improved verbal learning scores and stabilised a blood marker of neuronal damage (Yau et al., 2024). Both trials were small, so they establish plausibility rather than proof, and larger confirmatory trials are underway.

The fungal compound your gut absorbs through a dedicated channel

Much of the brain and longevity interest converges on one molecule: ergothioneine, a sulphur-containing antioxidant that fungi make and humans cannot synthesise at all. Its relationship with the gut is unusually intimate. Absorption depends on a specific transporter, OCTN1 (gene SLC22A4), first identified as a dedicated ergothioneine carrier and densely expressed on the lining of the small intestine, where it pulls the compound out of food (Gründemann et al., 2005; Cheah & Halliwell, 2023). The body then retains it for weeks and concentrates it in tissues under the most oxidative stress, including the brain, liver, eye, and blood (Cheah & Halliwell, 2023). Evolution does not build a dedicated gut transporter for a molecule it considers optional.

That logic led biochemist Bruce Ames to propose ergothioneine as a candidate “longevity vitamin,” one of a class of nutrients that cause no acute deficiency disease but whose long-term shortage may quietly accelerate ageing (Ames, 2018). It is not formally classified as a vitamin, and that proposal remains a hypothesis. But it is no longer hypothesis alone: in a Swedish cohort of more than three thousand people followed for over two decades, higher blood ergothioneine independently predicted lower cardiovascular disease and lower mortality (Smith et al., 2020). That is an association from an observational study, not proof of cause, since ergothioneine also marks a mushroom-rich, vegetable-rich diet. Mushrooms remain by far the richest dietary source.

Why an hour of sunlight rewrites a mushroom’s vitamin D

Mushrooms are rich in ergosterol, a fungal cousin of the precursor in your skin. Under ultraviolet light, ergosterol converts into vitamin D2, the same class of reaction that lets sunlight make vitamin D in human skin. Because commercial mushrooms grow in the dark, they carry almost no vitamin D at harvest, and the conversion after UV exposure is dramatic.

Crucially, this is not just a change on paper: in a randomised controlled trial, vitamin-D-deficient adults who ate soup made from UV-irradiated mushrooms raised their blood 25-hydroxyvitamin D as effectively as those taking a vitamin D2 supplement, and significantly more than placebo (Urbain et al., 2011). The popular tip to lay mushrooms in sunlight before eating is therefore sound, with refinements. In a controlled dose-response study, slicing the mushrooms and flipping them to expose both sides to the sun produced almost twice the vitamin D2 of exposing one side only (Urbain & Jakobsen, 2015). About an hour around midday, gills upward, captures most of the gain. Do not leave them out all day, since very prolonged exposure begins to degrade the vitamin.

Cooking to protect the payload

How you cook decides how much survives. When researchers compared boiling, frying, microwaving, and grilling across four common species, grilling and microwaving best preserved nutritional value and antioxidant activity, while boiling and frying caused the steepest losses as soluble compounds leached away (Roncero-Ramos et al., 2017). The same study found cooking method changed measurable beta-glucan content, so if you do simmer mushrooms, keep the liquid as stock rather than pouring it down the drain (Roncero-Ramos et al., 2017). Helpfully, ergothioneine is relatively heat-stable and survives normal cooking (Cheah & Halliwell, 2023).

Flavour rewards the same approach. Mushrooms are mostly water, so high dry heat from a grill, roast, or hard sear drives off moisture and concentrates their umami depth. Crowd the pan and they steam and turn rubbery. Give them room, let the water cook away, and let the surface brown.

The practical summary: eat a range of mushrooms regularly, sun them briefly if you want the vitamin D, save the cooking liquid, and favour the grill or a hot dry pan over the boiling pot.

---

References & Evidence Analysis

BiomeSci Study Grade rubric. A: strong, directly relevant human evidence (large RCTs, meta-analyses, or robust prospective cohorts with clinical or hard biomarker endpoints). B: moderate human evidence or rigorous expert synthesis (smaller RCTs, large observational cohorts, comprehensive systematic reviews, or well-controlled primary studies). C: preliminary or mechanistic (small pilot trials, single observational studies, in vitro, or hypothesis papers); included only where the finding is genuinely important. Grades reflect the strength of evidence for the specific claim the source supports here, not the overall importance of the work.

1. Wainright PO, Hinkle G, Sogin ML, Stickel SK. Monophyletic origins of the Metazoa: an evolutionary link with fungi. Science, 1993;260(5106):340-342. https://pubmed.ncbi.nlm.nih.gov/8469985/
Summary: The foundational molecular study showing animals and fungi share a more recent common ancestor with each other than with plants, the relationship later named Opisthokonta. Limitations: A single-gene (ribosomal RNA) analysis from 1993, since superseded in method, though its conclusion has been repeatedly confirmed by multi-gene work. Grade: B (foundational primary evidence, now consensus).

2. Sebé-Pedrós A, Degnan BM, Ruiz-Trillo I. The origin of Metazoa: a unicellular perspective. Nature Reviews Genetics, 2017;18(8):498-512. https://www.nature.com/articles/nrg.2017.21
Summary: An authoritative review synthesising comparative-genomic evidence that treats the animal-fungal (Opisthokonta) relationship as established and reconstructs the split between the lineages. Limitations: A review rather than primary data; evolutionary rather than clinical in scope. Grade: B (rigorous expert synthesis).

3. Zhong K, Liu Z, Lu Y, Xu X. Effects of yeast beta-glucans for the prevention and treatment of upper respiratory tract infection in healthy subjects: a systematic review and meta-analysis. European Journal of Nutrition, 2021;60(8):4175-4187. https://pubmed.ncbi.nlm.nih.gov/33900466/
Summary: Pooling thirteen randomised controlled trials, beta-glucan significantly reduced the incidence, episode count, and duration of upper respiratory tract infections versus placebo. Limitations: Yeast-derived rather than mushroom beta-glucan; some trials relied on self-reported infection; statistical heterogeneity between trials. Grade: A (meta-analysis of RCTs).

4. Maheshwari G, Gessner DK, Neuhaus K, et al. Effects of fungal beta-glucans on health: a systematic review of randomized controlled trials. Food & Function, 2021;12(14):6366-6389. https://pubs.rsc.org/en/content/articlehtml/2021/fo/d1fo00122a
Summary: Across thirty-four RCTs of fungal beta-glucans, including oyster, shiitake, and reishi sources, the consistent benefit was immune modulation reducing respiratory infection and allergy symptoms, with no glucan-related adverse events. Limitations: Wide range of sources and doses, many far below dietary mushroom levels; outcomes and preparations varied between trials. Grade: A/B (systematic review of RCTs).

5. Whitehead A, Beck EJ, Tosh S, Wolever TMS. Cholesterol-lowering effects of oat beta-glucan: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 2014;100(6):1413-1421. https://pmc.ncbi.nlm.nih.gov/articles/PMC5394769/
Summary: Twenty-eight RCTs showed oat beta-glucan at three grams or more daily significantly lowered LDL and total cholesterol. Limitations: Demonstrated for cereal (oat) beta-glucan, not the fungal type, so the result is cited here only to show what beta-glucan can do, not as direct evidence for mushrooms. Grade: A (for the oat-beta-glucan claim; an explicit extrapolation when applied to mushrooms).

6. Hess J, Wang Q, Gould T, Slavin J. Impact of Agaricus bisporus mushroom consumption on gut health markers in healthy adults. Nutrients, 2018;10(10):1402. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6213353/
Summary: In a randomised crossover trial, a high mushroom intake shifted microbial composition toward more Bacteroidetes and fewer Firmicutes and increased stool weight, but produced no change in short-chain fatty acids. Limitations: Small (n=32), short (10 days), whole mushrooms rather than isolated fibre, industry-funded, and no true baseline sample; partial fermentation was evident from undigested fragments. Grade: C (single small human trial; the key reason the microbiome claim is stated cautiously).

7. Zhang S, Tomata Y, Sugiyama K, et al. Mushroom consumption and incident dementia in elderly Japanese: the Ohsaki Cohort 2006 Study. Journal of the American Geriatrics Society, 2017;65(7):1462-1469. https://pubmed.ncbi.nlm.nih.gov/28295137/
Summary: Among more than thirteen thousand adults aged 65 and over followed for around six years, eating mushrooms three or more times weekly was associated with a 19 percent lower risk of incident dementia, with a significant dose-response trend. Limitations: Observational, so residual dietary and lifestyle confounding is possible; dementia ascertained through a care-insurance database. Grade: A (large prospective cohort with a clinical endpoint).

8. Aoki S, Yamagishi K, Maruyama K, et al. Mushroom intake and risk of incident disabling dementia: the Circulatory Risk in Communities Study (CIRCS). British Journal of Nutrition, 2024;131(9):1641-1649. https://www.cambridge.org/core/journals/british-journal-of-nutrition/article/mushroom-intake-and-risk-of-incident-disabling-dementia-the-circulatory-risk-in-communities-study-circs/8C7B169BE538A1CBC7B07E4A6DA76D69
Summary: Following nearly four thousand adults for a median of sixteen years, higher mushroom intake was associated with markedly lower risk of disabling dementia. Limitations: Observational; the protective association reached statistical significance only in women, not men, so the effect is not uniform. Grade: A (prospective cohort; note the sex-specific result).

9. Cha S, Bell L, Williams CM. The relationship between mushroom intake and cognitive performance: an epidemiological study in the EPIC-Norfolk cohort. Nutrients, 2024;16(3):353. https://pubmed.ncbi.nlm.nih.gov/38337638/
Summary: With mushroom intake tracked over roughly eighteen years, regular consumers performed better across several cognitive domains in a dose-dependent pattern. Limitations: Exposure is longitudinal but cognition was measured at a single later time point, so reverse causation cannot be fully excluded; observational design. Grade: B (long-term exposure data, cross-sectional cognitive outcome).

10. Mori K, Inatomi S, Ouchi K, Azumi Y, Tuchida T. Improving effects of the mushroom Yamabushitake (Hericium erinaceus) on mild cognitive impairment: a double-blind placebo-controlled clinical trial. Phytotherapy Research, 2009;23(3):367-372. https://onlinelibrary.wiley.com/doi/10.1002/ptr.2634
Summary: Over sixteen weeks, lion’s mane mushroom supplementation significantly improved cognitive-scale scores in older adults with mild cognitive impairment, with benefit declining after supplementation stopped. Limitations: Very small (n=30) and short, with a powdered supplement rather than whole mushrooms. Grade: B (randomised controlled trial, small sample).

11. Yau YF, Cheah IK, Mahendran R, et al. Investigating the efficacy of ergothioneine to delay cognitive decline in mild cognitively impaired subjects: a pilot study. Journal of Alzheimer’s Disease, 2024;102(3):841-854. https://pubmed.ncbi.nlm.nih.gov/39544014/
Summary: A year-long double-blind trial found ergothioneine supplementation improved verbal learning scores and stabilised plasma neurofilament light chain, a marker of neuronal damage, versus placebo. Limitations: A pilot with only 19 participants; results need confirmation in larger trials. Grade: B/C (RCT design, pilot scale).

12. Gründemann D, Harlfinger S, Golz S, et al. Discovery of the ergothioneine transporter. PNAS, 2005;102(14):5256-5261. https://www.pnas.org/doi/10.1073/pnas.0408624102
Summary: Identified SLC22A4 (OCTN1) as a high-affinity transporter dedicated to ergothioneine, transporting it far more efficiently than its other known substrates. Limitations: Cell and molecular work, not a clinical outcome study. Grade: A/B (well-replicated foundational biochemistry establishing the transporter).

13. Cheah IK, Halliwell B. Ergothioneine: an underrecognised dietary micronutrient required for healthy ageing? British Journal of Nutrition, 2023;129(1):104-114. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816654/
Summary: An authoritative review describing dense OCTN1 expression on the small-intestinal lining, ergothioneine’s accumulation in high-stress tissues, its heat stability, and the case for it as an under-recognised nutrient. Limitations: A narrative review, so it synthesises rather than tests; the “required for healthy ageing” framing remains a hypothesis. Grade: B (rigorous expert synthesis; used here for the absorption and retention facts).

14. Ames BN. Prolonging healthy aging: longevity vitamins and proteins. PNAS, 2018;115(43):10836-10844. https://doi.org/10.1073/pnas.1809045115
Summary: The conceptual paper introducing the “longevity vitamin” framework and naming ergothioneine among candidate nutrients whose long-term shortage may accelerate ageing. Limitations: A theoretical framework, not experimental evidence; the classification is a proposal, not a settled fact. Grade: C (foundational hypothesis, retained because the concept is central and genuinely important).

15. Smith E, Ottosson F, Hellstrand S, et al. Ergothioneine is associated with reduced mortality and decreased risk of cardiovascular disease. Heart, 2020;106(9):691-697. https://pmc.ncbi.nlm.nih.gov/articles/PMC7229907/
Summary: In a Swedish cohort of more than three thousand people followed over two decades, higher plasma ergothioneine independently predicted lower coronary disease, cardiovascular mortality, and all-cause mortality. Limitations: Observational; ergothioneine marks a mushroom- and vegetable-rich diet, so residual confounding cannot be excluded, and this is association, not causation. Grade: B (large prospective cohort with hard endpoints).

16. Urbain P, Singler F, Ihorst G, Biesalski HK, Bertz H. Bioavailability of vitamin D2 from UV-B-irradiated button mushrooms in healthy adults deficient in serum 25-hydroxyvitamin D: a randomized controlled trial. European Journal of Clinical Nutrition, 2011;65(8):965-971. https://pubmed.ncbi.nlm.nih.gov/21540874/
Summary: Over five weeks, vitamin-D-deficient adults eating UV-irradiated mushrooms raised their blood 25-hydroxyvitamin D as effectively as a vitamin D2 supplement and significantly more than placebo. Limitations: Small (n=26), short, single-blind, and using vitamin D2, which is somewhat less potent than D3 at maintaining status. Grade: A (randomised controlled trial with a blood biomarker endpoint).

17. Urbain P, Jakobsen J. Dose-response effect of sunlight on vitamin D2 production in Agaricus bisporus mushrooms. Journal of Agricultural and Food Chemistry, 2015;63(37):8156-8161. https://pubs.acs.org/doi/abs/10.1021/acs.jafc.5b02945
Summary: A controlled study showing sunlight rapidly converts mushroom ergosterol to vitamin D2, with slicing and exposing both sides producing almost double the vitamin D2 of one-sided exposure. Limitations: A food-chemistry study measuring mushroom content, not human vitamin D status. Grade: B (well-conducted primary analytical study).

18. Roncero-Ramos I, Mendiola-Lanao M, Pérez-Clavijo M, Delgado-Andrade C. Effect of different cooking methods on nutritional value and antioxidant activity of cultivated mushrooms. International Journal of Food Sciences and Nutrition, 2017;68(3):287-297. https://doi.org/10.1080/09637486.2016.1244662
Summary: Across four species, grilling and microwaving best preserved nutritional value and antioxidant activity while boiling and frying caused the greatest losses, with cooking method altering measurable beta-glucan content. Limitations: Measures composition and in-vitro antioxidant capacity, not human absorption or health outcomes. Grade: B (controlled primary food-science study; compositional endpoints only).